Summa Health /ID# 269349

Akron, Ohio 44304-1407

1 studies enrolling now · 1 studies all time

What they study most

Folate Receptor-Alpha Positive, Recurrent Ovarian Cancer

Studies at this site

• A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression — Recruiting now